Clinical Trials Logo

Fallopian Tube Cancer clinical trials

View clinical trials related to Fallopian Tube Cancer.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT04846842 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer. The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.

NCT ID: NCT04515602 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

Start date: January 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to answer the fundamental question 'The Optimal Timing of Surgery' in advanced ovarian cancer patients with different tumor burden, and to perform translational study.

NCT ID: NCT03180177 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer

EHNPCTASEOC
Start date: March 1, 2018
Phase: Phase 3
Study type: Interventional

This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy of hyperthermic intraperitoneal chemotherapy as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer . PR/SD rate, percentage of optimal debulking surgery and 3-year disease-free survival is the primary end points of this project.

NCT ID: NCT02435186 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Start date: June 2015
Phase: Phase 2
Study type: Interventional

The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

NCT ID: NCT01074398 Not yet recruiting - Ovarian Cancer Clinical Trials

Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

Start date: February 2010
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.